On Monday, the U.S. Supreme Court is set to hear a case that could decide whether genes can be patented. The ACLU, cancer patients, scientists and others sued Myriad Genetics — which owns the exclusive rights for two genes tied to breast and ovarian cancers — arguing the company limits patients’ access to affordable and accurate testing. But supporters say gene patents are necessary to incentivize research. What could the Court’s decision mean for scientists, patients and corporations?
Source: Forum Science